Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 12, 2020

SELL
$26.15 - $77.24 $387,020 - $1.14 Million
-14,800 Closed
0 $0
Q4 2019

Feb 11, 2020

SELL
$60.18 - $154.77 $1.87 Million - $4.8 Million
-31,000 Reduced 67.69%
14,800 $1.07 Million
Q3 2019

Nov 12, 2019

BUY
$140.29 - $189.96 $6.43 Million - $8.7 Million
45,800 New
45,800 $6.43 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Mufg Securities Emea PLC Portfolio

Follow Mufg Securities Emea PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mufg Securities Emea PLC, based on Form 13F filings with the SEC.

News

Stay updated on Mufg Securities Emea PLC with notifications on news.